BIO2023 / FDA CBER’s Peter Marks on COVID-19 Regulatory Impact
During a panel discussion at theBIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research (CBER) discussed the positive regulatory outcomes of the COVID-19…